公开(公告)号：US20050019889A1

公开(公告)日：2005-01-27

申请号：US10726645

申请日：2003-12-04

申请人： Gregg Hastings ,  Mark Adams ,  Claire Fraser ,  Norman Lee ,  Ewen Kirkness ,  Judith Blake ,  Lisa Fitzgerald ,  Fred Drake ,  Maxine Gowan

发明人： Gregg Hastings ,  Mark Adams ,  Claire Fraser ,  Norman Lee ,  Ewen Kirkness ,  Judith Blake ,  Lisa Fitzgerald ,  Fred Drake ,  Maxine Gowan

IPC分类号： G01N33/53 ,  A61K31/70 ,  A61K38/00 ,  A61K38/46 ,  A61K38/48 ,  A61K39/395 ,  A61K48/00 ,  A61P19/08 ,  A61P19/10 ,  A61P35/00 ,  A61P43/00 ,  C07H21/00 ,  C07H21/02 ,  C07H21/04 ,  C07K14/47 ,  C07K16/40 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N9/48 ,  C12N9/50 ,  C12N9/64 ,  C12N15/09 ,  C12N15/11 ,  C12N15/57 ,  C12N15/66 ,  C12P19/34 ,  C12P21/00 ,  C12P21/02 ,  C12P21/08 ,  C12Q1/37 ,  G01N33/535

CPC分类号： C12N9/6472 ,  A61K38/00 ,  C07K16/40

摘要： Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.

摘要翻译： 公开了一种人破骨细胞来源的组织蛋白酶（组织蛋白酶O）多肽和编码这种组织蛋白酶O多肽的DNA（RNA）。 还提供了通过重组技术产生这种多肽的方法。 本发明还公开了这种多肽的抗体，拮抗剂和抑制剂，其可用于预防这种多肽的作用，因此可用于治疗性治疗骨疾病如骨质疏松症和癌症如肿瘤转移。

公开(公告)号：US20060024299A1

公开(公告)日：2006-02-02

申请号：US11185877

申请日：2005-07-21

申请人： Gregg Hastings ,  Mark Adams ,  Claire Fraser ,  Norman Lee ,  Ewen Kirkness ,  Judith Blake ,  Lisa Fitzgerald ,  Fred Drake ,  Maxine Gowan

发明人： Gregg Hastings ,  Mark Adams ,  Claire Fraser ,  Norman Lee ,  Ewen Kirkness ,  Judith Blake ,  Lisa Fitzgerald ,  Fred Drake ,  Maxine Gowan

IPC分类号： C12Q1/68 ,  C07H21/04 ,  C12P21/06 ,  A61K39/395 ,  C12N9/64

CPC分类号： C12N9/6472 ,  A61K38/00 ,  C07K16/40

摘要： Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.

公开(公告)号：USD260751S

公开(公告)日：1981-09-15

申请号：US73671

申请日：1979-09-10

申请人： Norman Lee ,  Thomas E. Douglas

设计人： Norman Lee ,  Thomas E. Douglas

公开(公告)号：US20150252432A1

公开(公告)日：2015-09-10

申请号：US14639219

申请日：2015-03-05

申请人： Norman Lee ,  Bi-Dar Wang

发明人： Norman Lee ,  Bi-Dar Wang

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/158 ,  G01N33/5011

摘要： A method of classifying a patient for eligibility for cancer therapy based on the presence or absence of splicing variants in a sample of the patient's cancer tissue. Also, a method of screening cancer therapies for efficacy against splicing variants. More specifically, the methods relate to novel splicing variants of genes associated with cancer risk and survival, particularly splicing variants of PIK3CD, FGFR3, TSC2, RASGRP2, ITGA4, MET, NF1 and BAK1. Also more specifically, the methods relate to classifying a patient for eligibility for cancer therapy involving the use of GS-1101.

摘要翻译： 基于患者癌症组织的样品中剪接变体的存在或不存在，对患者进行癌症治疗的资格进行分类的方法。 另外，筛选针对剪接变体的功效的癌症疗法的方法。 更具体地，该方法涉及与癌症风险和存活相关的基因的新剪接变体，特别是PIK3CD，FGFR3，TSC2，RASGRP2，ITGA4，MET，NF1和BAK1的剪接变体。 更具体地说，该方法涉及将病人分类为涉及使用GS-1101的癌症治疗的资格。

公开(公告)号：USD256682S

公开(公告)日：1980-09-02

申请号：US54711

申请日：1979-07-05

申请人： Norman Lee ,  Thomas E. Douglas

设计人： Norman Lee ,  Thomas E. Douglas

公开(公告)号：US09988687B2

公开(公告)日：2018-06-05

申请号：US14639219

申请日：2015-03-05

申请人： Norman Lee ,  Bi-Dar Wang

发明人： Norman Lee ,  Bi-Dar Wang

IPC分类号： C12Q1/68 ,  C12P19/34 ,  G01N33/50

CPC分类号： C12Q1/6886 ,  C12Q2600/158 ,  G01N33/5011

摘要： A method of classifying a patient for eligibility for cancer therapy based on the presence or absence of splicing variants in a sample of the patient's cancer tissue. Also, a method of screening cancer therapies for efficacy against splicing variants. More specifically, the methods relate to novel splicing variants of genes associated with cancer risk and survival, particularly splicing variants of PIK3CD, FGFR3, TSC2, RASGRP2, ITGA4, MET, NF1 and BAK1. Also more specifically, the methods relate to classifying a patient for eligibility for cancer therapy involving the use of GS-1101.

公开(公告)号：USD255762S

公开(公告)日：1980-07-08

申请号：US903998

申请日：1978-05-08

申请人： Norman Lee ,  Clayton J. Ammondson

设计人： Norman Lee ,  Clayton J. Ammondson